Key result
PCSK9 inhibition boosts LDLR-dependent selective HDL-cholesteryl ester clearance and steroidogenesis in mice.
Why the study?
The effects of PCSK9 depletion or inhibition on selective HDL cholesteryl ester uptake, the contribution of LDLR, and the physiological relevance remained to be elucidated.
Does PCSK9 deletion or inhibition increase LDLR-mediated selective HDL cholesteryl ester uptake and adrenal steroidogenic responsiveness in mice?
Does PCSK9 deletion or inhibition increase LDLR-mediated selective HDL cholesteryl ester uptake and adrenal steroidogenic responsiveness in mice?
Identifies the PCSK9-LDLR axis as a key regulator of selective HDL cholesteryl ester trafficking to the liver and adrenals, linking PCSK9 inhibition to enhanced ACTH-stimulated adrenal steroidogenesis in mice.
Answers are grounded in this paper and cite their sources.
PCSK9 inhibition may affect adrenal steroidogenesis in mice; leaves open relevance to human endocrine function or therapy.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a central regulator of hepatic low-density lipoprotein receptor (LDLR) abundance and plasma LDL cholesterol. PCSK9 also modulates high-density lipoprotein (HDL) composition in mice and humans. Plasma HDL levels are regulated by intravascular remodeling and hepatic selective HDL cholesteryl ester (CE) uptake. In addition to the dominant scavenger receptor class B type I (SR-BI), LDLR contributes to this uptake process in liver and adrenals, probably by mediating interactions with an HDL subclass containing apoE. Hepatic cholesterol can be converted to bile acids for biliary excretion, while internalized cholesterol is used for steroid hormone synthesis in adrenals. However, the effects of PCSK9 depletion/inhibition on selective HDL-CE uptake, the contribution of LDLR, and the physiological relevance remain to be elucidated. We used HDL dual-labelled in its protein and CE components to distinguish selective CE uptake from HDL holoparticle clearance. Mice with targeted Pcsk9 deletion had increased selective HDL-CE clearance from plasma and greater CE uptake by liver and adrenals, without a proportional increase in HDL protein-tracer uptake. This phenotype persisted in primary PCSK9-deficient hepatocytes exposed to identical WT-derived HDL. In WT mice, a PCSK9-neutralizing monoclonal antibody increased hepatic LDLR abundance, selective HDL-CE clearance, and organ uptake. These clearance effects were absent in LDLR-deficient mice. Basal plasma corticosterone, the principal glucocorticoid in mice, was unchanged, whereas ACTH-stimulated corticosterone was higher after PCSK9 inhibition. These findings identify the PCSK9-LDLR axis as a determinant of selective HDL-CE trafficking and link PCSK9 activity to adrenal steroidogenic responsiveness in mice.
No takes yet. Share an insight, caveat, or question.
Heine et al. (2026) studied Lipoprotein metabolism and adrenal steroidogenesis. Targeted Pcsk9 deletion or PCSK9-neutralizing monoclonal antibody vs. Wild-type mice and LDLR-deficient mice was evaluated on Selective HDL cholesteryl ester (CE) plasma clearance, hepatic/adrenal uptake, and ACTH-stimulated corticosterone levels. PCSK9 deletion or antibody inhibition increased LDLR-dependent selective HDL-CE clearance, hepatic and adrenal uptake, and ACTH-stimulated corticosterone in mice.
Synapse has enriched 10 related papers. Consider them for comparative context: